In CMV D+/R− liver transplant recipients beyond the early post-transplant period who have CKD and recurrent leukopenia but can obtain reliable weekly labs, what specific thresholds (e.g., CMV DNAemia trajectory, absolute neutrophil count patterns, ability to respond rapidly to rising PCR) make you choose pre-emptive PCR monitoring over valganciclovir prophylaxis, or vice versa?